1. Home
  2. PACK vs SLN Comparison

PACK vs SLN Comparison

Compare PACK & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ranpak Holdings Corp

PACK

Ranpak Holdings Corp

N/A

Current Price

$5.08

Market Cap

653.6M

ML Signal

N/A

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$13.27

Market Cap

678.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PACK
SLN
Founded
1972
1994
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
653.6M
678.0M
IPO Year
2017
2010

Fundamental Metrics

Financial Performance
Metric
PACK
SLN
Price
$5.08
$13.27
Analyst Decision
Buy
Buy
Analyst Count
3
5
Target Price
$6.50
$42.60
AVG Volume (30 Days)
595.9K
1.6M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$395,000,000.00
$559,000.00
Revenue This Year
$9.29
N/A
Revenue Next Year
$8.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.08
N/A
52 Week Low
$3.22
$4.19
52 Week High
$7.81
$17.58

Technical Indicators

Market Signals
Indicator
PACK
SLN
Relative Strength Index (RSI) 37.34 57.07
Support Level $4.73 $5.24
Resistance Level $5.71 $17.58
Average True Range (ATR) 0.22 1.01
MACD -0.00 -0.08
Stochastic Oscillator 24.62 37.82

Price Performance

Historical Comparison
PACK
SLN

About PACK Ranpak Holdings Corp

Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: